Pfizer Inc (PFE.DU)
| Previous close | 23.92 |
| Open | 24.00 |
| Bid | 24.00 x 0 |
| Ask | 24.07 x 0 |
| Day's range | 23.95 - 24.09 |
| 52-week range | 23.59 - 37.40 |
| Volume | |
| Avg. volume | 113 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Yahoo Finance Video
Pfizer raises full-year outlook, stock rises on Q1 beat
Pfizer (PFE) shares tick up in pre-market trading — continuing into the green after the market open — after the pharmaceutical giant raised its full-year profit outlook and topped first-quarter earnings estimates on the top and bottom lines. Yahoo Finance Health Reporter Anjalee Khemlani joins The Morning Brief to discuss Pfizer's outlook on its future product pipeline. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Luke Carberry Mogan.
GuruFocus.comPfizer Inc (PFE) Q1 2024 Earnings: Adjusted EPS Surpasses Expectations Amidst Revenue Decline
Key Financial Metrics and Strategic Insights
Barrons.comPfizer Stock Rises as Outlook Rises After Earnings Beat
Pfizer bumped up its earnings guidance on Wednesday while reporting better financial results than expected as it works to regain investors’ confidence after a disastrous 2023. More notable was the increase in earnings guidance. “This increase takes into consideration both our improving line of sight to our cost savings target, and continued strength in our underlying business,” CFO David Denton said in prepared remarks distributed ahead of the company’s Wednesday morning investor call.
